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Abstract
Background: Triptolide (TP), an active constituent of Tripterygium wilfordii, possesses numerous pharmacological
activities. However, its effects on cytochrome P450 enzymes (CYP450s) in rats remain unexplored.
Methods: In this study, the effects of triptolide on the six main CYP450 isoforms (1A2, 2C9, 2C19, 2D6, 2E1, and 3A)
were investigated both in vivo and in vitro. We monitored the body weight, survival proportions, liver index,
changes in pathology, and biochemical index upon TP administration, in vivo. Using a cocktail probe of CYP450
isoform-specific substrates and their metabolites, we then carried out in vitro enzymatic studies in liver microsomal
incubation systems via ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS).
Finally, we verified our results at the messenger ribonucleic acid (mRNA) and protein level through quantitative
real-time polymerase chain reaction (RT-qPCR), western blotting, and immunohistochemical detection.
Results: The in vivo toxicity study confirmed that Sprague-Dawley (SD) rats exhibited dose-dependent
hepatotoxicity after intragastric administration of TP [200, 400, and 600 μg/(kg.day)] for 28 days. In case of the
CYP450 isoforms 3A, 2C9, 2C19, and 2E1, the in vitro metabolic study demonstrated a decrease in the substrate
metabolic rate, metabolite production rate, and Vmax, with an increase in the Km value, compared with that
observed in the control group. Additionally, a TP dose-dependent decrease in the mRNA levels was observed in the
four major isoforms of CYP3A subfamily (3A1/3A23, 3A2, 3A9, and 3A62) and CYP2C9. A similar effect was also
observed with respect to the protein levels of CYP2C19 and CYP2E1.
Conclusions: This study suggests that TP can cause hepatotoxicity by reducing the substrate affinity, activity, and
expression at the transcriptional and protein levels of the CYP450 isoforms 3A, 2C9, 2C19, and 2E1. TP also has the
potential to cause pharmacokinetic drug interactions when co-administered with drugs metabolized by these four
isoforms. However, further clinical studies are needed to evaluate the significance of this interaction.
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Background
Triptolide (TP) (Fig. 1a) is a major bioactive diterpenoid
isolated from the traditional Chinese medicinal herb
Tripterygium wilfordii Hook F (TWHF). It shows
promising anti-inflammatory, immunomodulatory, anti-
proliferative, proapoptotic, and neuroprotective activities
[1–6]. However, its clinical application is limited owing to
acute and chronic side effects induced in multiple organs.
According to the China Food and Drug Administration
(CFDA), commercial preparations of T. wilfordii were re-
sponsible for 633 adverse reaction cases from 2004 to
2011 September, including 53 severe cases that involved
reproductive toxicity, hepatotoxicity, and renal cytotox-
icity among other outcomes [7]. The mechanism under-
lying to TP-induced liver injury is caused by many
reasons. In L-02 cells, TP decreased mitochondrial mem-
brane potential and Bcl-2, promoted the release of
* Correspondence: zxp@njutcm.edu.cn
†Equal contributors
1The First Clinical College, Nanjing University of Chinese Medicine, Nanjing,
Jiangsu, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lu et al. BMC Complementary and Alternative Medicine  (2017) 17:15 
DOI 10.1186/s12906-016-1504-3
cytochrome c, and up-regulated the expression of Bax,
P53 and caspase 3 via the mitochondrial apoptotic path-
way [8]. It was also reported that TP treatment signifi-
cantly increased ROS levels and decreased GSH levels,
decreased the protein expression of Nrf2 and its target
genes including HO-1 and MRP2 except NQO [9]. Recent
research also indicates the abnormal metabolism of Cyto-
chrome P450s (CYP450s) enzyme system plays an import-
ant role.
Drug-induced toxicity is caused either by the parent
compounds or by their reactive metabolites generated
primarily through biotransformation in the liver [10].
CYP450s, a monooxygenase family with comprehensive
detoxification, which play a dominant role in the redox
metabolism of numerous endobiotics [11] and xenobi-
otics [12], are closely associated with the toxic effects of
TP [13, 14]. According to a previous study, TP was
absorbed, distributed, and monohydroxylated rapidly in
the liver after oral administration [15]. Further, in vitro
data indicated that the metabolism of TP was mediated
by both CYP3A4 and CYP2C19 [16]. Additionally, dexa-
methasone, a CYP3A agonist, was observed to markedly
Fig. 1 Related chemical structures. a The chemical structure of TP. b The chemical structure of the cocktail probe
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accelerate the metabolism of TP and thus attenuate hep-
atotoxicity in vivo [17]. TP is also reported to inhibit
CYP3A4 expression and activity [18]. Thus, the CYP3A
subfamily has been reported to play an important role in
TP-induced hepatotoxicity [18, 19].
However, the underlying mechanisms of TP-induced
toxicity mediated by the CYP450 family have not been
well delineated. Since abnormal drug metabolism by
CYP450s also plays an important role in the hepatotox-
icity, the enzymes might trigger drug-drug interactions
(DDIs) between TP and other co-administered drugs,
thereby, causing the observed toxicity. In this study, we
focused on understanding the role of CYP450s in medi-
ating TP-induced hepatotoxicity. We demonstrated that
TP disturbed the activity and expression of CYP450s in
the liver, through UHPLC-MS/MS, RT-qPCR, and west-
ern blot analyses. We also evaluated the TP-induced in
vivo hepatotoxicity using several physiological and bio-
chemical indices. Our study focused on the six main iso-
forms of CYP450s: 1A2, 2C9, 2C19, 2D6, 2E1, and 3a.
These six isoforms account for more than 80% of the hep-
atic CYP450s, and metabolize more than 90% of the clin-
ically approved drugs [20]. The substrates, metabolites in
the cocktail probe used in this study are shown in (Fig. 1b).
Based on the results obtained, we concluded that CYP3A,
CYP2C9, CYP2C19, and CYP2E1 were the CYP450 sub-
family members most affected by TP.
Methods
Chemicals and reagents
TP (CAS No. 38748-32-2), tolbutamide (D860), mid-
azolam (MDZ), chlorzoxazone (CLZ), caffeine (CAF),
paraxanthine, 4-hydroxytolbutamide, ±−−4-hydroxyme-
phenytoin, dextrorphan, 1-hydroxymidazolam, diazepam,
NADPH, D-glucose-6-phosphate disodium salt, and
glucose-6-phosphate dehydrogenase were purchased from
Sigma-Aldrich (St. Louis, MO, USA). S-mephenytoin (MT)
and 6-hydroxychlorzoxazone were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Dextrome-
thorphan (DM) was obtained from the National Institute
for the Control of Pharmaceutical and Biological Products
(Beijing, China). High-performance liquid chromatography-
grade acetonitrile, methanol, formic acid, and ethyl acetate
were obtained from Merck (Darmstadt, Germany). Deion-
ized water was obtained using a Milli-Q® system (Millipore
Corporation, Billerica, MA). Quantitative detection kits
for Alanine aminotransferase (ALT)、aspartate amino-
transferase (AST)、total protein (Tp)、globulin(GLB)、al-
bumin(ALB)、triglycerides (TG)、total cholesterol (T-
chol)、and glucose (Glu) were obtained in Beijing Lead-
man Biochemistry Technology Co. Ltd (Beijing China).
Carbon monoxide was obtained from Nanjing Weichuang
Gas Co. Ltd. (Nanjing, China). Radioimmunoprecipitation
assay buffer, phenylmethanesulfonyl fluoride (PMSF), and
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) sample loading buffer were purchased
from Beyotime Institute of Biotechnology (Jiangsu, China).
Polyvinylidene difluoride (PVDF) membranes were ob-
tained from Millipore (Shanghai, China). Rabbit anti-rat
CYP2C19 polyclonal antibody and rabbit anti-rat CYP2E1
polyclonal antibody were purchased from Abcam (Cam-
bridge, MA, USA). The bicinchoninic acid (BCA) protein
assay kit was purchased from Thermo Fisher Scientific
(Waltham, MA, USA). All other chemicals and solvents
used were of analytical grade.
Animals and experimental design
Since the toxic effects of TP are significantly different
between different sexes [21], we specifically chose female
SD rats for our study. All animal studies were performed
with the approval of the Institutional Animal Care and
Use Committee of Nanjing University of Chinese Medi-
cine, and were performed according to the guidelines of
the National Institutes of Health for the Care and Use of
Laboratory Animals (NIH publication No. 80–23). Fe-
male SD rats (180–220 g) were purchased from the
Charles River Experimental Animal Company (Beijing,
China). All rats were housed in an air-conditioned ani-
mal quarter at a temperature of 23–27 °C and a relative
humidity of 45–55%, with ad libitum access to water
and food. The animals were acclimatized to the facilities
for a week and then fasted, with free access to water for
12 h prior to each experiment. The rats were randomly
divided into four groups of 12 animals each. While the
control group rats received the vehicle alone, the three
TP group rats received different concentrations of TP
(200 μg/(kg.day), 400 μg/(kg.day), and 600 μg/(kg.day),
once daily for 28 days. During the experiment, the rats
were generally monitored on a daily basis and their body
weights were measured weekly. After the final drug ad-
ministration, the rats were fasted overnight, anesthetized
with 10% chloral hydrate (0.35 mL/100 g) by intraperito-
neal injection, and then sacrificed. Blood samples were
drawn and the livers were collected for further analysis.
In vivo toxicity study
The liver samples were immediately weighed for liver
index calculation (liver weight × 100%/body weight) and
frozen in liquid nitrogen. Abdominal aortic blood was
drawn and centrifuged at 3000 rpm for 5 min (4 °C) to
collect the blood serum for the determination of ALT,
AST, Tp, ALB, TG, T-chol, and GLU levels by using an
automatic biochemistry analyzer (LX20, Beckman Coulter
Inc., Miami, FL, USA). Slices of the same part of the livers
were cut and fixed in phosphate-buffered 10% formalde-
hyde solution and then embedded in paraffin wax. Sec-
tions of liver tissue were cut and stained with hematoxylin
and eosin and examined for histopathological changes
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under an Olympus DX45 microscope (Olympus Corpor-
ation, Tokyo, Japan). The images were taken using an
Olympus DP72 camera (Olympus Corporation, Tokyo,
Japan) at an original magnification of 200 × .
In vitro metabolic study
Preparation and appraisal of rat liver microsomes
Rat liver microsomes were obtained via differential centrifu-
gation [22] (L-80XP, Microfuge® 16, Beckman Coulter Inc.,
Miami, FL, USA). The microsomes were stored in buffer
[10 mM Tris-acetate, 1 mM ethylenediaminetetraacetic
acid (EDTA), 100 mM PMSF, and 20% glycerol, pH: 7.4] at
−80 °C until further use. Protein concentrations were deter-
mined by the BCA method and CYP450 content was deter-
mined by the method of Omura and Sato [23].
Study of CYP450 activity in in vitro microsomal incubation
systems
The enzymatic activities of P450 isoforms were character-
ized based on the reactions shown in (Fig. 1b). The micro-
somal incubation system (200 μL) consisted of a buffer
[10% sucrose, 100 mM EDTA, 1 mM PMSF, 2 mM dithio-
threitol (DTT), and 100 mM phosphate-buffered saline
(PBS), pH 7.4], an NADPH regeneration system (0.2 mM
NADP+, 2 mM glucose-6-phosphate, and 0.4 IU glucose-
6-phosphate dehydrogenase), hepatic microsomes [0.5 mg
(protein)/mL], an inhibitor, and a cocktail probe (CAF/
D860/MT/DM/CLZ/MDZ: 15/20/10/10/5/2.5 μM) [24].
After pre-incubation in a shaking incubator block
(Eppendorf Thermomixer 5436, Hamburg, Germany) for
5 min at 37 °C the reaction was initiated by adding
NADP+ (0.2 mM). The reactions were performed at 37 °
C for 30 min and terminated by the addition of 200 μL
of ice-cold methanol - acetonitrile (1: 1, V: V) solution,
which contained Diazepam (8 μg/mL) as an internal
standard (ISTD). The mixtures were immediately cooled
in an ice bath to precipitate the proteins, then shaken
and centrifuged for 10 min at 12000 rpm. An aliquot of
20 μL of the supernatant was injected for UHPLC–MS/
MS analysis to test the final concentration of substrates
and metabolites. The substrate metabolic rate (%) and
the production of the metabolites [nmol/(protein g ×
min)] was used as the enzyme activity index.
To estimate the kinetic parameters, the microsomes
were incubated with different concentrations of the
cocktail probe (diluted by half dilution method as listed
in Table 1). The concentration of each metabolite was
determined by UHPLC-MS/MS at different timepoints
(1, 2, 4, 6, and 10 min) and the metabolic rate was calcu-
lated by linear regression analysis. The Vmax and Km
value of each CYP450 isoform was calculated by non-
linear regression analysis of experimental data according
to the Michaelis–Menten model of enzyme kinetics,
using the Prism 5.0 program:
V ¼ Vmax S½ 
Km þ S½ ð Þ
Where V is the metabolic rate; Vmax is the maximum
velocity; Km is the Michaelis–Menten constant; [S] is
the substrate concentration.
UHPLC–MS/MS-ESI analysis
Chromatographic separations were carried out on an
Agilent 1290 UHPLC system (Agilent Technologies,
Santa Clara, CA, USA) using an Agilent ZORBAX
RRHD Eclipse Plus C18 column (2.1 × 50 mm inner
diameter,1.8 μm particle size) (Agilent Technologies,
Santa Clara, CA, USA). The elution profile was com-
posed of an initial isocratic step with water (0.1% formic
acid): acetonitrile (ACN) (95:5) for 1.5 min and then in-
creasing ACN to 30% over 4 min to separate the sub-
strates and metabolites at 30 °C. The column was
washed with 90% of ACN for 2.5 min followed by the
equilibration of the column for 5 min with 5% ACN.
The flow rate was 0.4 mL/min and the injection volume
was 5 μL. An Agilent 6460 triple quadrupole-mass spec-
trometer with an electrospray ion source (Agilent Tech-
nologies, Santa Clara, CA, USA) was used for flow
injection analysis with optimized fragmentor and source
parameters. The optimized source parameters for MS
analysis were drying gas temperature, 350 °C; gas flow,
10 L/min; nebulizer gas flow pressure, 35 psi; and capil-
lary voltage, 4500 V.
Verification of observed effects at the mRNA and protein
level
Quantitative real-time polymerase chain reaction
While implementing this experiment, we realized that
human CYP3A subfamily isoforms, such as CYP3A4,
CYP3A43, CYP3A7, etc., have several commercially
available antibodies; however, there are no such anti-
bodies for the main CYP3A subfamily isoforms (e.g.
CYP3A1, CYP3A2, etc.) and CYP2C9 of rats. In order
to validate the metabolic study and further probe the
specific roles of the CYP3A subfamily and CYP2C9, we
measured the mRNA expression of five major CYP3A
Table 1 The cocktail probe of different concentration (μM)
Substrates Concentration Number
1 2 3 4 5 6 7
Caffeine(CAF) 1.875 3.75 7.5 15 30 60 120
Tolbutamide(D860) 0.625 1.25 2.5 5 10 20 40
(S)- Mephenytoin(MT) 1.25 2.5 5 10 20 40 60
Dextromethorphan(DM) 2.5 5 10 20 40 80 160
Chlorzoxazone(CLZ) 1.25 2.5 5 10 20 40 60
Midazolam(MDZ) 0.313 0.625 1.25 2.5 5 10 20
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subfamily isoforms (CYP3A1/3A23, CYP3A2, CYP3A9,
CYP3A18, and CYP3A62) [25–28] and CYP2C9 using
RT-qPCR. Frozen tissue samples were homogenized in
1 mL Trizol® reagent and total RNA was extracted fol-
lowing the manufacturer’s protocol. After ethanol pre-
cipitation, the vacuum-dried RNA was dissolved in
50 μL nuclease-free water, and the concentration and
purity of isolated RNA was determined by absorbance
at 260 nM. The 260/280 nM ratios of the samples were
between 1.8 and 2.0. RNA purity and concentration
was assessed using a NanoDrop 2000 spectrophotom-
eter (Thermo Fisher Scientific Waltham, MA, USA).
Thus, cDNA synthesis was performed at 50 °C for
60 min by adding 7 μL of the RT master mix (“Prime-
ScriptTM RT Master Mix RR036A (TaKaRa, Tokyo,
Japan)) and terminated by incubating for 15 min at
75 °C. Distilled water was added to the reaction mix-
ture to a final volume of 100 μL. Real-time qPCR was
performed with an ABI® 7500 system (Life Technolo-
gies Corporation, Gaithersburg, MD, USA) using the
2x SYBR® Select Master Mix (Thermo Fisher Scientific,
Waltham, MA, USA) for the detection of PCR prod-
ucts. β-actin was used as an internal control. The pri-
mer pairs used were as listed in Table 2. Amplification
was done with a hot start polymerase activation step
for 10 min at 95 °C, followed by 40 cycles of 15 s at
95 °C and 1 min at 60 °C, and the cycle threshold (CT)
values of the target gene were identified. All samples
were run in triplicates.
Western blotting
The total protein extract was prepared by diluting 50 μL
liver microsome suspension with 1 volume of radioim-
munoprecipitation assay (RIPA) lysis buffer (150 mM
NaCl, 1% Nonidet™ P-40 (NP-40), 0.5% sodium deoxy-
cholic acid, 0.1% SDS, and 50 mM Tris-Cl, pH 7.5) for
15 min and then centrifuging at 13,000 rpm 4 °C for
10 min. Aliquots containing 20 μg of protein were sepa-
rated by SDS-PAGE on a 10% gradient gel (Invitrogen,
Carlsbad, CA, USA) and transferred to a PVDF membrane
which was blocked with 5% non-fat dry milk in Tris-
buffered saline with Tween 20 (TBST) (200 mM Tris–
HCl, 1.37 M NaCl, 0.1% Tween 20, pH 7.6) for 1 h.
The membrane was then incubated with rabbit anti-
rat CYP2C19 polyclonal antibody (1:2000 dilution), rabbit
anti-rat CYP2E1 polyclonal antibody (1:1000 dilution) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody (1:2000 dilution), overnight at 4 °C. After rinsing
five times with TBST, for 5 min each time, at 20 °C, the
membrane was incubated with horseradish peroxidase
(HRP)-labeled anti-rabbit immunoglobulin G (IgG) anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The immunoreactive bands were visualized using an en-
hanced chemiluminescence detection system (ChemiDoc™
XRS+, Bio-Rad, Hercules, CA, USA) and quantified by
densitometry using ImageJ 1.41 (National Institutes of
Health, Bethesda, Maryland, USA) software.
Immunohistochemical detection
The tissue sections were incubated with rabbit anti-rat
CYP2C19 polyclonal antibody (1:200 dilution) and rabbit
anti-rat CYP2E1 polyclonal antibody (1:100 dilution) in
blocking solution (0.4% (v/v) Triton X-100 and 3% (v/v)
normal goat serum (NGS) in PBS) for 1 h. After incuba-
tion, the slices were washed four times, for 10 min each
time, with 0.01 M PBS. Then, the sections were again in-
cubated for 2 h with anti-rabbit antibody (1:500 dilution)
at room temperature. After several PBS washes, the anti-
body complex was detected using a modification of the
ABC system (Vectastain® ABC kit, Vector Laboratory
Inc., Burlingame, CA, USA). The immunoreactive cells
were stereologically quantified using Image-Pro Express
6 (Media Cybernetics, CA, USA) software. The selected
areas were digitized with an Olympus DX45 micro-
scope (Olympus Corporation, Tokyo, Japan). The im-
ages were taken using an Olympus DP72 camera
(Olympus Corporation, Tokyo, Japan) at an original
magnification of 400 × .
Statistical analysis
SPSS version 19.0 for Windows (IBM Corp, Armonk, NY,
USA) was used for all statistical analyses. All experiments
were performed at least thrice. Comparisons were made
between two groups using two-sided Student’s t test and
among multiple groups using one-way ANOVA followed
by Tukey’s post hoc test. Data are expressed as Mean ± SD
and P < 0.05 was considered statistically significant.
Table 2 Primers used in RT-PCR















Lu et al. BMC Complementary and Alternative Medicine  (2017) 17:15 Page 5 of 15
Results
In vivo toxicity study
General observation and survival proportions
After one-week administration of TP, the rats began to
exhibit restlessness by jumping up and down. Some rats
showed reduced spontaneous activity and were less re-
sponsive to outside stimulations. During the second
week, the groups which were administered 400 and
600 μg/(kg.day) of TP began showing symptoms of mor-
tality. In the third and fourth week, the rats of the TP
groups showed several symptoms of severe poisoning
such as arched vertical hair, squinting or closed eyes, re-
duced activity, diarrhea, weight loss, and death. Of the
rats that lived through the 28-day treatment period, 11
were from the 200 μg/(kg.day) group, 8 were from the
400 μg/(kg.day) group, and 6 were from the 600 μg/
(kg.day) group. The number of deaths observed during
the 28 days is presented in (Fig. 2a).
Effects of TP on the body weight of rats
Before the treatment with TP, there was no significant dif-
ference in body weight among the four groups. After the
28-day treatment period, the body weight of TP-treated rats
was markedly decreased (P < 0.05 or P < 0.01), especially
during the latest week of measurement, compared with the
steadily increasing trend observed in the control group.
Among the TP treated groups, the group which re-
ceived with 600 μg/(kg.day) of TP demonstrated a
dramatic weight loss compared with that observed in
other groups (P < 0.01). These experimental results are
shown in (Fig. 2b).
Effects of TP on the liver index of rats
After the rats were sacrificed, the livers were placed on
ice and weighed. The control group livers were dark red
in color with bright red cut surfaces, soft and normal
volumes, and smooth capsules. In contrast, the TP group
livers were swollen with purple or dark cut surfaces.
Based on the statistical analysis, there was no significant
difference in liver index between the control and TP-
treated groups (Fig. 2c).
Effects of TP on hepatic histopathology
Microscopically, the control group showed no major re-
markable pathological changes. After the oral adminis-
tration of TP for (200, 400, and 600 μg/(kg/.day)) for
28 days, the rats showed significant histopathological
changes, mainly including apparent liver cell degener-
ation of liver cell and inflammatory cell infiltration of in-
flammatory cells in the hepatic lobules and portal area,
as shown in (Fig. 2d-g).
Effects of TP on biochemical indicators
As shown in Fig. 3, after the oral administration of either
the vehicle or TP (200, 400, and 600 μg/(kg.day)) for
28 days, significant increase (P < 0.05 or P < 0.01) in the
Fig. 2 General and pathological study in vivo. a Survival proportions during oral administration of TP of different dosage. b Effects of TP of
different dosage on body weight in rats: Rats were orally treated with vehicle or 200, 400 or 600 μg/kg/day of TP for 28 days. Symbols and bars
represent the mean ± SD, respectively; *P < 0.05, **P < 0.01 versus the control group. c Effects of TP of different dosage on liver index in rats
showed no significant difference. d-g Pathological study of liver from the control group (d), 200 μg/kg/day (e), 400 μg/kg/day(f), or 600 μg/kg/
day (g) for 28 days. d showed no remarkable changes; (e-f) showed apparent degeneration of liver cell, infiltration of inflammatory cells in
hepatic lobules and portal area
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levels of ALT, AST, T-chol, Trig, and GLU and signifi-
cant decrease (P < 0.05 or P < 0.01) in the levels of Tp
and ALB were observed in the TP groups in comparison
with that observed in the control group. Thus, most of
the biochemical indicators changed in a TP dosage-
dependent manner compared with the observed values
in the control group. However, there was no significant
difference in GLB levels (see Additional file 1).
In vitro metabolic study
Effects of TP on rat liver microsomes
No significant difference in microsomal protein concen-
tration was observed in TP group when compared to that
in the control group (Fig. 4a). However, TP treatment
caused a significant decrease (P < 0.01) in the micro-
somal CYP450 content (Fig. 4b), with the 400 μg/
(kg.day) dose group exhibiting maximal suppression
(58.3%) of CYP450 content.
Chromatography-mass behavior and specificity study
Since our initial efforts were focused on monitoring the
changes in CYP450 content upon oral administration of
TP, we explored whether the six main CYP450 isoform-
specific substrates and their metabolites were suitable
for use in cocktail incubations. We thus established a
cocktail assay for simultaneous determination of the activ-
ities of six main CYP450 isoforms in liver microsomes
using UHPLC-MS/MS, with a cocktail probe consisting of
the isoform-specific substrates, metabolites, and an in-
ternal standard. The multiple reaction monitoring (MRM)
transitions, optimized fragmentor voltage, collision en-
ergy, and selected reaction monitoring (SRM) pairs of
Fig. 3 Effect of triptolide on biochemical indicators after orally treated with vehicle or 200, 400 or 600 μg/kg/day of triptolide for 28 days, the
biochemical indicators exhibited significant increases of ALT (a), AST (b), T-chol (f), Trig (g). GLU (l), and significant decreases of Tp (c), ALB (d)
were also observed. There shows no significant difference in GLB (e). Results are expressed as mean ± SD of each group, respectively;*P < 0.05,
**P < 0.01 significantly different from the control group
Fig. 4 The effects of protein concentrations and CYP450s content of liver microsomes. a Effects of TP on the microsomal protein concentration
showed no significant difference. b CYP450s content of liver microsomes showed a significant decrease (P < 0.01) after the TP administration of
all the different dosages. Results are expressed as mean ± SD of each group, respectively;*P < 0.05, ** P < 0.01 significantly different from the
control group
Lu et al. BMC Complementary and Alternative Medicine  (2017) 17:15 Page 7 of 15
each substrate and its metabolite are reported in Table 3.
The specificity of the tandem mass spectrometer allowed
a fast liquid chromatography gradient to be employed.
Representative chromatograms for substrates and metabo-
lites in the microsomal incubation mixtures are presented
in Fig. 5. There was no interference from other substrates
or metabolites at any of the retention times of interest for
any metabolite MRM channel.
Stability tests showed that samples remained stable
even after being placed at room temperature for 24 h
and being subjected to three repeated freeze-thaw cycles.
In the precision test, the average standard deviation of
three substances corresponding to the peak area was <
5%. The recovery rate test showed that both the absolute
and method recovery rates were > 90%.
Effects of TP on the substrates and metabolites of CYP450
enzymes
In this study we determined the enzyme activity index in
terms of the substrate metabolic rate and the metabolite
production rate [nmol/(protein g × min)]. After oral ad-
ministration of either the vehicle or TP (200, 400 or
600 μg/(kg.day)) for 28 days, the liver microsomes were
incubated with the cocktail probe (CAF/D860/MT/DM/
CLZ/MDZ: 15/20/10/10/5/2.5 μM) for 30 min. The final
concentrations of the substrates and metabolites were
detected by UHPLC-MS/MS. Although the metabolic rates
of CYP1A2 and CYP2D6 remained the same, the rates of
other CYP450s showed significant changes (P < 0.05
or P < 0.01) in TP-treated groups than in the control
group (Fig. 6a). While the metabolic rates of CYP2C19
(71.3%) and CYP3A (40.2%) decreased in the 200 μg/
(kg.day) TP group, the rates of CYP2C19 (58.1%), CYP3A
(35.4%), CYP2E1 (77.2%), and CYP2C9 (64.6%) were de-
creased in the 400 μg/(kg.day) TP group. Similarly, the
600 μg/(kg.day) TP group showed a more dramatic de-
crease in the rates of CYP2C19 (41.1%), CYP3A (31.6%),
CYP2E1 (75.9%), and CYP2C9 (51.1%). Similar decreases
(P < 0.05 or P < 0.01) were also seen in the metabolite pro-
duction rates in TP-treated groups in comparison with
that observed in the control group (Fig. 6b). While the
metabolite production rates of CYP2C19 (70.1%) and
CYP3A (40.2%) decreased in the 200 μg/(kg.day) TP
group, the rates of CYP2C19 (58.1%), CYP3A (35.4%),
CYP2E1 (66.7%), and CYP2C9 (28.1%) decreased in the
400 μg/(kg.day) TP group. The 600 μg/(kg.day) TP group
showed a more dramatic decrease in the metabolite produc-
tion rates of CYP2C19 (41.1%), CYP3A (31.6%), CYP2E1
(39.8%), and CYP2C9 (27.4%) (See Additional file 2).
Thus, when compared with the control group, 28-day
TP administration inhibited either the substrate reduc-
tion or metabolite production. Further, decrease in the
activities of CYP450s became more pronounced with the
increase in TP dosage.
Effects of TP on the kinetic parameters of CYP450 family
In this study, we observed the production of the metabo-
lites [nmol/(protein g ×min)] by incubating the micro-
somes with different concentrations of the substrates.
The Km and Vmax values of each CYP450 isoform were
calculated by non-linear regression analysis of experi-
mental data according to the Michaelis–Menten model
of enzyme kinetics, using the Prism 5.0 program. As
shown in Fig. 7, after oral administration of either the
vehicle or TP (200, 400 or 600 μg/(kg.day)) for 28 days,
the liver microsomes were incubated with different con-
centrations of the cocktail probe (CAF/D860/MT/DM/
CLZ/MDZ) for 1, 2, 4, 6, and 10 min. In the TP-treated
groups, the Km values of CYP1A2 and CYP2D6
remained the same while the corresponding values of
Table 3 MRM chromatogram by UHPLC/MIS/MS method for each subject from a normal assay sample
component Corresponding CYP450s parent ion daughter ion Fragmentor /V Collision energy/V polarity
Caffeine(CAF) CYP1A2 195.0 137.8 100 20 ESI+
Tolbutamide(D860) CYP2C9 269.1 169.8 110 13 ESI-
(S)-Mephenytoin(MT) CYP2C19 219.0 134.0 100 17 ESI+
Dextromethorphan(DM) CYP2D6 272.0 214.9 155 25 ESI+
Chlorzoxazone(CLZ) CYP2E1 168.0 131.8 120 17 ESI-
Midazolam(MDZ) CYP3A 326.0 291.0 106 25 ESI+
Paraxanthine CYP1A2 181.0 123.9 120 21 ESI+
4-Hydroxy Tolbutamide CYP2C9 287.0 74.2 95 13 ESI+
(+/−)-4-Hydroxy Mephenytoin CYP2C19 235.0 150.0 90 17 ESI+
Dextrorphan CYP2D6 258.2 157.0 145. 40 ESI+
6-Hydroxy chlorzoxazone CYP2E1 183.9 64.1 100 33 ESI-
1-Hydroxymidazolam CYP3A 342.0 324 162 21 ESI+
Diazepam(DZP) ISTD 285.0 193.0 159 33 ESI+
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other CYP450s showed significant changes (P < 0.05 or
P < 0.01), in comparison with the control group values.
The 200 μg/(kg.day) TP group exhibited an increase in
the Km values of CYP2C19 (1.31 fold) and CYP3A (1.23
fold). Similarly, the 400 μg/(kg.day) TP group exhibited
an increase in the Km values of CYP2C19 (1.30 fold),
CYP3A (1.78 fold), CYP2E1 (1.45 fold), and CYP2C9
(1.59 fold). The 600 μg/(kg.day) TP group showed a
more dramatic increase in the Km values of CYP2C9
(1.91 fold), CYP3A (2.08 fold), CYP2E1 (1.47 fold), and
CYP2C19 (1.33 fold). The metabolite production rates
followed a decreasing trend (P < 0.05 or P < 0.01) in the
TP-treated groups in comparison to that observed in the
control groups. While the metabolite production rates of
CYP2C19 (87.8%) and CYP3A (58.8%) were decreased in
the 200 μg/(kg.day) TP group, the rates of CYP2C19
(68.7%), CYP3A (77.5%), and CYP2C9 (75.4%) were de-
creased in the 400 μg/(kg.day) TP group. The 600 μg/
(kg.day) TP group showed a more dramatic decrease in
the metabolite production rates of CYP2C19 (60.9%),
CYP3A (65.7%), CYP2C9 (60.0%), and CYP2E1 (85.9%)
(see Additional file 3).
The Km value represents the affinity of a CYP450 en-
zyme for its specific substrate while the Vmax value rep-
resents the theoretical maximum metabolic rate of the
substrate in the incubation system. These two parame-
ters are very important indicators in the study of the
kinetics of enzyme-catalyzed reactions. In comparison
with the Km and Vmax value trends of CYP450s in the
control groups, the trends observed in the TP-treated
groups after the 28-day treatment period reflected the
inhibitory effects of TP on CYP450 activity. Further, this
TP-induced inhibition of CYP450 activity became more
pronounced with the increase in TP dosage.
Verification in mRNA and protein level
Effect on mRNA expression of CYP3A and CYP2C9
After oral administration of either the vehicle or TP (200,
400 or 600 μg/(kg.day)) for 28 days, the mRNA levels of
many CYP3A subfamily isoforms and CYP2C9 in TP-
treated groups showed a significant decrease (P < 0.05 or P
< 0.01) in comparison with that observed in the control
group (Fig. 8a). The 200 μg/(kg.day) TP group exhibited
decreased CYP3A2 (49.8%) and CYP3A62 (86.2%), and
Fig. 5 Chromatograms of substrates, metabolites and the internal standard. (A-F): Substrates[A: Caffeine(CAF);B: Tolbutamide(D860);C: (S)-
Mephenytoin(MT);D: Dextromethorphan(DM);E:Chlorzoxazone(CLZ);F: Midazolam(MDZ)]. (H-M) metabolites [H:Paraxanthine;I:4-Hydroxy
Tolbutamide;J:(+/−)-4-Hydroxy Mephenytoin;K:Dextrorphan;L:6-Hydroxy chlorzoxazone;M:1-Hydroxymidazolam]. (G) The internal
standard: Diazepam(DZP)
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increased CYP3A9 (1.17 fold) mRNA expression. The
400 μg/(kg.day) TP group also exhibited decreased CYP3A2
(37.8%), CYP3A62 (61.5%), CYP3A1/3A23 (73.7%), and
CYP3A9 (84.8%) mRNA expression. The 600 μg/(kg.day)
TP group exhibited a stronger decrease in CYP3A1/3A23
(61.8%), CYP3A2 (23.2%), CYP3A9 (60.6%), and CYP3A62
(55.2%) mRNA expression. Expression of CYP2C9 mRNA
in the 200, 400, and 600 μg/(kg.day) TP groups decreased
in a dose-dependent manner to 72.3, 66.3, and 28.2%, re-
spectively, in comparison with that observed in the control.
Effect on protein expression of CYP2C19 and CYP2E1
When the effects of TP on CYP450 protein expression in
rat liver microsomes were studied (Fig. 8b-c), TP was ob-
served to decrease the protein expression of CYP2C19 and
CYP2E1 in a dose-dependent manner (P < 0.05 or P < 0.01),
in comparison to that observed in the control. The 600 μg/
(kg.day) TP group exhibited a particularly strong decrease in
CYP2C19 (41.9%) and CYP2E1 (51.4%) protein expression.
Results of the immunohistochemical detection of
CYP2C19 and CYP2E1 in rat liver sections were as
shown in (Fig. 8d-e). TP was observed to decrease
CYP2C19 and CYP2E1 expression in immunoreactive
cells in a dose-dependent manner (P < 0.05 or P < 0.01),
in comparison to that observed in the control. The
immunoreactive cells of the 600 μg/(kg.day) TP group
exhibited a particularly strong decrease in CYP2C19
(27.5%) and CYP2E1 (38.2%) expression.
Discussion
Based on pre-experimental observations, we found that
TP-induced liver injury was more severe and stable in
female rats than in male rats. Hence, female SD rats
were specifically selected for this study. We found a
certain correlation between the dosages of TP and
hepatotoxicity in rats, which was consistent with pre-
viously published results [7, 21]. The TP-treated groups ex-
hibited histopathological changes. Additionally, changes in
the biochemical indicators suggested that the mechanisms
Fig. 6 Effects of TP on the CYP450s enzyme activity. a The effect of TP on the substrate metabolic rate. After orally treated with vehicle or 200,
400 or 600 μg/kg/day of triptolide for 28 days, the liver microsomes were incubated with the cocktail probe (CAF/D860/MT/DM/CLZ/MDZ: 15/20/
10/10/5/2.5 μM) for 30 mins. The final concentration of the substrates and metabolites were detected by UPLC-MS/MS. the substrate metabolic
rate of CYP1A2, CYP2D6 after the 30-min-incubation in vitro remained the same but other CYP450s showed significant changes. The 200 μg/kg/
day TP group exhibited decreases in CYP2C19 and CYP3A; then the 400 and 600 μg/kg/day TP group exhibited decreases not only in CYP2C19
and CYP3A, but also CYP2E1 and CYP2C9. b The effect of TP on the production of the metabolites. After the administration, the 200 μg/kg/day
TP group showed decreases in CYP2C19 and CYP3A, then the 400 and 600 μg/kg/day TP group also exhibited decreases in CYP2E1 and CYP2C9.
Results are expressed as mean ± SD of each group, respectively;*P < 0.05, ** P < 0.01 significantly different from the control group
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Fig. 7 Effects of TP on the CYP450s kinetic parameters. a-f The Michaelis–Menten data of each CYP450s. After orally treated with vehicle or 200,
400 or 600 μg/kg/day of triptolide for 28 days, the liver microsomes incubated with the cocktail probe (CAF/D860/MT/DM/CLZ/MDZ) in different
concentration (diluted with half dilution method as listed in Table 1) and a NADPH-generating system at 37 °C. The concentration of the each
metabolites were detected by UPLC-MS/MS at the incubation time of 1, 2, 4, 6, 10 min, the rate of metabolism were calculated from linear regression
analysis. The rate of metabolism [nmol/(protein g ×min)] versus the concentration of each substrates was fit to The Michaelis–Menten equation. Data
represents the mean of three independent experiments in duplicate determinations. g-h The Km (g) and Vmax values (h) were calculated from non-
linear regression analysis of experimental data according to the Michaelis–Menten models for the kinetics of each CYP450s with Prism 5.0 program.
Results are expressed as mean ± SD of each group, respectively;*P< 0.05, ** P< 0.01 significantly different from the control group
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of liver injury differed with different TP dosages and would
be progressed by higher concentration.
An intensive understanding of the CYP450 dysregula-
tion phenomenon in TP-induced liver injury is necessary
because of its significance in guiding the drug dosage in
patients who require the co-administration of other
drugs with TP. As shown in Fig. 4, TP decreased the ac-
tivities of CYP2C19, CYP2C9, CYP2E1 and the CYP3A
subfamily without attenuating the liver microsomal pro-
tein concentration. CYP3A, which metabolizes 60% of
all clinical drugs, is the most important enzyme for drug
metabolism. In our study, the result about CYP3A con-
firmed its major role in the metabolism of TP. It should
be noted that drugs which are metabolized by CYP3A
should be avoided or reasonably adjusted when co-
administered with TP or its related preparations, orally.
The metabolic activation of carcinogens and toxins is
mainly mediated by CYP2E1 [29, 30], and drugs of the
nervous system are mainly metabolized by the CYP2C
subfamily [31, 32]. Clinicians should therefore closely
monitor the patient’s liver-related indices and adjust the
medication when co-administering drugs which are
mainly metabolized by these CYP450s along with TP to
avoid toxic side effects.
In our study, we observed a TP dose-dependent de-
crease in the mRNA expression of most CYP3A subfam-
ily isoforms and CYP2C9, which was consistent with the
results of our metabolic study. Among the five main
CYP3A isoforms in rats, the expression of CYP3A2
and CYP3A62 mRNAs was most sensitive to TP-induced
toxicity. The expression of CYP3A1/3A23 and CYP3A9
mRNAs was also significantly decreased at higher TP
Fig. 8 Verification in mRNA and protein level. a Effect of triptolide on mRNA levels of CYP3A family and CYP2C9 in livers of rats. Liver lysates were
made from livers of rats. b Protein lysates were made from microsomes of rats’ liver and subjected to Western blot analysis using the indicated
antibodies. The GAPDH was used as an internal control. A representative blot from three rats in each group was shown. The density of
the immunoreactive bands was analyzed as(c). d Immunohistochemical detection of CYP2C19 and CYP2E1 in livers section of rats was
shown. The Immunoreactive cells were stereo logically quantified (e). Symbols and bars represent the mean ± SD, respectively; *p < 0.05,
**p < 0.01 versus the control group
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dosages, while there was no such inhibitory effect on
CYP3A18. This phenomenon may have been due to the
use of adult rats in this experiment, as CYP3A18 expression
is strongly correlated with growth hormone production
[33]. CYP3A4 was reported to be primarily responsible for
the hydroxylation of TP in the human liver [16]. In vitro
studies of TP with CYP isoforms and P-glycoprotein (P-gp)
indicate that TP has the potential to cause pharmacokinetic
drug interactions when co-administered with other drugs
metabolized by CYP1A2 and CYP3A4 [34]. As the major
member of CYP3A subfamily in rats, CYP3A1/3A23 and
CYP3A2 had 89% in their amino acid sequences [35], and
CYP3A2 was reported to be specifically expressed in male
rats [36]. In this study, we found that CYP3A2 played
a very important role in the dysregulation of CYP450
activity due to TP-induced liver injury, in female rats
as well. In spite of the sequence similarity, many
functional differences exist between CYP3A1/3A23
and CYP3A2. [28]. In our study, while the mRNA ex-
pression pattern of CYP3A62 and CYP3A9 showed
similar trends in the 400 and 600 μg/(kg.day) TP groups,
the trends were completely different in the 200 μg/
(kg.day) TP group. This phenomenon may have been due
to the metabolic difference exhibited by different concen-
trations of TP and needs to be investigated further.
CYP2C9, an important component of the liver enzyme
system, comprises about 10% of the total liver CYP450
enzyme content and is involved in the metabolism of
10% of the drugs in clinical trials [37]. In this study, we
observed that CYP2C9 activity in the 200 μg/(kg.day) TP
group was not inhibited although its mRNA expression
was significantly decreased, after the administration of
TP for 28 days. But in the 400 and 600 μg/(kg.day) TP
groups, the enzyme affinity, activity, and mRNA expres-
sion of CYP2C9 were significantly decreased, thus con-
firming the dose-dependent inhibitory effect of TP on
CYP2C9.
According to our results, the protein expression of
CYP2C19 and CYP2E1 decreased in a TP dose-dependent
manner, which was consistent with the results of our
metabolic study. Besides the CYP3A subfamily, CYP2C19
is also reported to be involved in TP metabolism and tox-
icity [16, 34], and is therefore being actively researched.
High doses of TP have been previously reported to signifi-
cantly upregulate the levels of CYP2E1 mRNA in compari-
son with that observed in the control, after intragastric
administration of TP (0.05, 0.3 and 0.6 mg/(kg.day)) for 7
consecutive days [38]. However, in our study, we observed
a significant decrease in CYP2E1 enzyme affinity and ac-
tivity in TP-treated groups, and the protein expression
study further confirmed this inhibitory effect of TP. We
speculate that the difference between our findings and
those of the previous report [38] may be due to a differ-
ence in the time of intragastric administration of TP.
This experimental research demonstrated the abnor-
mal metabolism of CYP450 enzyme system after TP ad-
ministration. This results will hopefully serve as useful
information for further understanding of the underlying
mechanisms of TP-induced subacute toxicity. This re-
sults also suggests that when the patient needs to take
TP for a certain time, doctors should pay attention to
avoid the co-administration with drugs which metabo-
lized by CYP3A, CYP2C9, CYP2C19, CYP2E1. If the
co-administration was inevitable, doctors should closely
observe the liver function.
There are several limitations in our work. First, the
relationship between CYP450 dysregulation and TP-
induced hepatotoxicity remains undefined because we
did not determine the exact mechanism through which
TP affects CYP450 activity. Second, although we ob-
served the effect of different concentrations of TP on
CYP450 activity, the effect of different times of drug
administration still needs to be investigated. Finally, all
our experiments were conducted in rat liver microsomes
or tissues; therefore, the effects of TP on real patients
need to be investigated in the future.
Conclusions
In summary, intragastric administration of TP (200, 400,
and 600 μg/(kg.day)) for 28 consecutive days can cause
hepatotoxicity by reducing the substrate affinity, activity,
and expression at the transcriptional and protein level of
CYP3A, CYP2C9, CYP2C19, and CYP2E1. TP also has
the potential to cause pharmacokinetic drug interactions
when co-administered with drugs metabolized by these
four CYP450 isoforms. However, further clinical studies
are needed to evaluate the significance of this interaction.
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